Founded in 2009, Galera Therapeutics develops small-molecule dismutase mimetics that replicate the body’s superoxide dismutase enzymes. In pre-clinical models these compounds simultaneously attack tumors and protect healthy tissue from damage caused by radiation therapy, chemotherapy, and cytokine immunotherapies. The company’s lead program targets prevention of oral mucositis, a debilitating side effect of cancer therapy, and is positioned to move directly into Phase 2a human proof-of-concept studies thanks to extensive prior clinical experience in non-cancer indications. Beyond oral mucositis, Galera intends to leverage its proprietary platform to address additional side effects of cancer treatment. The team is led by inventor Dennis Riley, Ph.D., and includes experienced executives and drug developers. Financially, the company has secured a Series “1” financing of undisclosed size to fund its lead program and platform expansion; no revenue or user metrics were provided in the article.

Total raised

$138M

Funding rounds

6

Latest round

Series C

Latest activity

Sep 2018